Dr. Andrew Faucheux is a medical oncologist and hematologist at Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana. He received his medical degree from LSU Health Shreveport School of Medicine, where he was inducted into the Alpha Omega Alpha Honor Medical Society. Dr. Faucheux completed his residency in internal medicine at Wake Forest University School of Medicine, where he served as chief resident, and completed his fellowship in hematology and oncology at Wake Forest.
Dr. Faucheux has a strong background in clinical research, medical education, and physician leadership. Since 2020, his work has contributed to numerous peer-reviewed publications and national presentations focused on immunotherapy, lung cancer, hematology, and supportive oncology care. He is an active member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH).
As a medical oncologist and hematologist, Dr. Faucheux works closely with the Mary Bird Perkins Cancer Center team to provide compassionate, individualized care for each patient's unique needs.
Mary Bird Perkins Cancer Center Louisiana Hematology Oncology Associates
Fellowship: Wake Forest University School of Medicine; Winston-Salem, NC (hematology and oncology) Diplomate: American Board of Internal Medicine Chief Residency: Wake Forest University School of Medicine; Winston-Salem, NC (internal medicine) Residency: Wake Forest University School of Medicine; Winston-Salem, NC (internal medicine)
Medical: LSU Health Shreveport School of Medicine; Shreveport, LA Graduate: Mississippi College; Clinton, MS Undergraduate: Louisiana State University; Baton Rouge, LA
American Board of Internal Medicine (Hematology, Medical Oncology)
Faucheux, A., Bloomer, C., Quattlebaum, A. M., Khoury, L., Olson, E., Omlor, R., & Lycan, T. (2023). Barriers to palliative care in the immunotherapy era: End-of-life outcomes among a retrospective cohort of metastatic lung cancer patients. Journal of Pain and Symptom Management, 65(5), e586.
Faucheux, A., Klepin, H. D., Levine, B. J., Quattlebaum, A. M., Bloomer, C. H., Khoury, L. M., Hunting, J., Elko, C. A., Olson, E., & Lycan, T. W. (2023). Impact of comorbidity burden on immune-related adverse events and survival among older adults with cancer on immunotherapy. Journal of Clinical Oncology, 41(16_suppl), 12061.
Faucheux, A., Olson, E., Hunting, J., Klepin, H. D., Elko, C. A., Deyo, L. J., & Lycan, T. W., Jr. (2024). Routine documentation of pre-treatment functional variables to predict survival in patients on immunotherapy. Journal of Clinical Oncology, 42(16_suppl), e14701.
Guo, A. A., Knapp, M.-P., Evans, J. K., Faucheux, A., Price, S. N., Klepin, H. D., Levine, B., Quattlebaum, A., Bloomer, C., Khoury, L., Hunting, J. C., Elko, C. A., Olson, E., & Lycan, T. W., Jr. (2025). Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy. Future Oncology, 21(14), 1787–1796.
Hunting, J. C., Price, S. N., Faucheux, A., Olson, E., Elko, C. A., Quattlebaum, A., Ruiz, J., & Lycan, T. W., Jr. (2025). Survival impact of immune-related adverse events in extensive stage small cell lung cancer patients: a retrospective cohort study. Immunotherapy, 17(1), 19–24.
Burcher, K., Faucheux, A., Lantz, J., Wilson, H. L., Abreu, A., Salafian, K., Patel, M., Song, A., Petro, R., Lycan, T., Furdui, C., Topaloglu, U., D’Agostino, R., Zhang, W., & Porosnicu, M. (2021). Prevalence of DNA repair gene mutations in blood and tumor tissue and impact on prognosis and treatment in HNSCC. Cancers, 13(13), 3118.
Hunting, J., Price, S., Deyo, L., Knapp, M. P., Faucheux, A., Olson, E., & Lycan, T. (2024). Comparative differences of irAE between extensive stage small cell lung cancer and non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 12(Suppl 2).
